Cargando…

Pitavastatin and Ivermectin Enhance the Efficacy of Paclitaxel in Chemoresistant High-Grade Serous Carcinoma

SIMPLE SUMMARY: The main challenge in high-grade serous carcinoma management is to unveil therapeutic approaches to overcome chemoresistance. Drug combinations and repurposing of non-oncological agents are attractive strategies that allow for higher efficacy, decreased toxicity, and the overcoming o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nunes, Mariana, Duarte, Diana, Vale, Nuno, Ricardo, Sara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496819/ https://www.ncbi.nlm.nih.gov/pubmed/36139522 http://dx.doi.org/10.3390/cancers14184357

Ejemplares similares

The Antineoplastic Effect of Carboplatin Is Potentiated by Combination with Pitavastatin or Metformin in a Chemoresistant High-Grade Serous Carcinoma Cell Line
por: Nunes, Mariana, et al.
Publicado: (2022)

Generation of Two Paclitaxel-Resistant High-Grade Serous Carcinoma Cell Lines With Increased Expression of P-Glycoprotein
por: Nunes, Mariana, et al.
Publicado: (2021)

Corrigendum: Generation of Two Paclitaxel-Resistant High-Grade Serous Carcinoma Cell Lines With Increased Expression of P-Glycoprotein
por: Nunes, Mariana, et al.
Publicado: (2022)

Ivermectin Augments the Anti-Cancer Activity of Pitavastatin in Ovarian Cancer Cells
por: Jawad, Mohammed Jasim, et al.
Publicado: (2023)

CCNE1 expression in high grade serous carcinoma does not correlate with chemoresistance
por: Sapoznik, Stav, et al.
Publicado: (2017)

Combination of Antimalarial and CNS Drugs with Antineoplastic Agents in MCF-7 Breast and HT-29 Colon Cancer Cells: Biosafety Evaluation and Mechanism of Action
por: Duarte, Diana, et al.
Publicado: (2022)

Epigenetic Mechanisms and Therapeutic Targets in Chemoresistant High-Grade Serous Ovarian Cancer
por: Matthews, Bayley G., et al.
Publicado: (2021)

Pleiotropic effects of pitavastatin
por: Davignon, Jean
Publicado: (2012)

Ascitic Senescent T Cells Are Linked to Chemoresistance in Patients With Advanced High-Grade Serous Ovarian Cancer
por: Zhang, Jie, et al.
Publicado: (2022)

Efficacy and Safety of Pitavastatin/Ezetimibe Fixed-Dose Combination vs. Pitavastatin: Phase III, Double-Blind, Randomized Controlled Trial
por: Tsujita, Kenichi, et al.
Publicado: (2023)

Prediction of Drug Synergism between Peptides and Antineoplastic Drugs Paclitaxel, 5-Fluorouracil, and Doxorubicin Using In Silico Approaches
por: Vale, Nuno, et al.
Publicado: (2022)

Identification of Chemoresistance-Associated Key Genes and Pathways in High-Grade Serous Ovarian Cancer by Bioinformatics Analyses
por: Wu, Yong, et al.
Publicado: (2020)

Abnormal methylation characteristics predict chemoresistance and poor prognosis in advanced high-grade serous ovarian cancer
por: Feng, Li-yuan, et al.
Publicado: (2021)

Interaction of the pitavastatin with model membranes
por: Shurshalova, Guzel S., et al.
Publicado: (2021)

Efficacy and Safety of Pitavastatin in a Real-World Setting: Observational Study Evaluating SaFety in Patient Treated with Pitavastatin in Korea (PROOF Study)
por: Jeong, In-Kyung, et al.
Publicado: (2020)

miR-708-5p enhances erlotinib/paclitaxel efficacy and overcomes chemoresistance in lung cancer cells
por: Monteleone, Nicholas J., et al.
Publicado: (2020)

Concurrent Primary Peritoneal Low-Grade Serous Carcinoma and Endometrial High-Grade Serous Carcinoma
por: Lockyer, Megan G., et al.
Publicado: (2015)

Efficacy and Safety of Pitavastatin in Children and Adolescents with Familial Hypercholesterolemia in Japan and Europe
por: Harada-Shiba, Mariko, et al.
Publicado: (2018)

DNA methylation and transcriptomic features are preserved throughout disease recurrence and chemoresistance in high grade serous ovarian cancers
por: Gull, Nicole, et al.
Publicado: (2022)

Primary high-grade serous ovarian cancer cells are sensitive to senescence induced by carboplatin and paclitaxel in vitro
por: Uruski, Paweł, et al.
Publicado: (2021)

Pitavastatin in cardiometabolic disease: therapeutic profile
por: Masana, Luis
Publicado: (2013)

Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel
por: Seino, Manabu, et al.
Publicado: (2018)

MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis
por: Zanotti, Laura, et al.
Publicado: (2017)

Low-grade Serous Ovarian Carcinoma
por: Ricciardi, Enzo, et al.
Publicado: (2018)

Mini-Review on the Efficacy and Safety of Pitavastatin: “The Novel Seventh Statin Gaining Momentum”
por: Ramadan, Azza, et al.
Publicado: (2022)

In vivo efficacy of pitavastatin combined with itraconazole against Aspergillus fumigatus in silkworm models
por: Majima, Hidetaka, et al.
Publicado: (2023)

Correction: Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel
por: Seino, Manabu, et al.
Publicado: (2021)

Pitavastatin: evidence for its place in treatment of hypercholesterolemia
por: Alagona, Peter
Publicado: (2010)

Effect of Pitavastatin on Vascular Reactivity in Hypercholesterolemic Rabbits
por: de Almeida, Eros Antonio, et al.
Publicado: (2014)

Bilateral Serous Psammocarcinoma of Ovary: Rare Variant Low Grade Serous Carcinoma
por: Jena, Saubhagya Kumar, et al.
Publicado: (2015)

TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer
por: Wang, Ning, et al.
Publicado: (2012)

Spatially resolved transcriptomics of high-grade serous ovarian carcinoma
por: Stur, Elaine, et al.
Publicado: (2022)

The Continuum of Serous Tumors of Low Malignant Potential and Low-Grade Serous Carcinomas of the Ovary
por: Wong, Kwong-Kwok, et al.
Publicado: (2007)

Effect of Pitavastatin Treatment on ApoB-48 and Lp-PLA(2) in Patients with Metabolic Syndrome: Substudy of PROspective Comparative Clinical Study Evaluating the Efficacy and Safety of PITavastatin in Patients with Metabolic Syndrome
por: Lee, Hyo-Sun, et al.
Publicado: (2016)

Pitavastatin approved for treatment of primary hypercholesterolemia and combined dyslipidemia
por: Sasaki, Jun
Publicado: (2010)

Statins in cardiometabolic disease: what makes pitavastatin different?
por: Ginsberg, Henry
Publicado: (2013)

Pitavastatin suppressed liver cancer cells in vitro and in vivo
por: You, He-Yi, et al.
Publicado: (2016)

Differential Diabetogenic Effect of Pitavastatin and Rosuvastatin, in vitro and in vivo
por: Cho, Yongin, et al.
Publicado: (2020)

Pitavastatin Is a Highly Potent Inhibitor of T-Cell Proliferation
por: Voss, Linda, et al.
Publicado: (2021)

ABTL0812 enhances antitumor effect of paclitaxel and reverts chemoresistance in triple‐negative breast cancer models
por: Polonio‐Alcalá, Emma, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7fvsj153ch6ag8u716jqosd81a